SOPHiA GENETICS SA (SOPH) – What Are Analysts Thinking About This Stock?

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $10.00.

Several brokerages have recently commented on SOPH. HC Wainwright lifted their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. BTIG Research raised their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th.

SOPHiA GENETICS Trading Up 1.5%

Shares of SOPH opened at $7.41 on Tuesday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS has a 12-month low of $3.75 and a 12-month high of $8.98. The firm has a market capitalization of $621.62 million, a PE ratio of -6.44 and a beta of 0.95. The stock’s fifty day simple moving average is $7.91 and its 200-day simple moving average is $6.16.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. As a group, research analysts predict that SOPHiA GENETICS will post -0.77 earnings per share for the current year.

Insider Buying and Selling at SOPHiA GENETICS

In other SOPHiA GENETICS news, insider Philippe Menu sold 7,394 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $8.13, for a total value of $60,113.22. Following the transaction, the insider owned 200,993 shares of the company’s stock, valued at approximately $1,634,073.09. This represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Manuela Valente sold 4,240 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $8.13, for a total value of $34,471.20. Following the transaction, the insider owned 206,210 shares in the company, valued at approximately $1,676,487.30. This trade represents a 2.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 291,543 shares of company stock valued at $2,181,326 over the last quarter. 4.88% of the stock is owned by corporate insiders.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Silverberg Bernstein Capital Management LLC raised its position in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after purchasing an additional 4,155 shares during the period. Principal Financial Group Inc. grew its position in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. 1492 Capital Management LLC increased its stake in SOPHiA GENETICS by 8.4% during the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after purchasing an additional 17,406 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares in the last quarter. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.